Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model

Epidemiology and Infection

Volumn 124, Issue 2, 2000, Pages 295-307

  Wilson, J N ^a   Nokes, D J ^a   Carman, W F ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ARTICLE; DEMOGRAPHY; GAMBIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MATHEMATICAL MODEL; NONHUMAN; TIME; VIRUS MUTANT; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BIRTH RATE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FORECASTING; GAMBIA; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; MUTATION; NONLINEAR DYNAMICS; PREVALENCE; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES;

EID: 0034048756     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268800003605     Document Type: Article

References (29)

1. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15: 757-66.
2. Cariani E, Ravaggi A, Fiordalisi G, et al. Emergence of a novel HBsAg escape mutant in a liver-transplant recipient. Hepatology 1994; 20: A307-A.
3. Cariani E, Ravaggi A, Tanzi E, et al. Emergence of hepatitis-B virus S-gene mutant in a liver-transplant recipient. J Med Virol 1995; 47: 410-5.
4. Ngui SL, O'Connell S, Eglin RP, Heplonstall J. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 1997; 176: 1360-5.
5. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9.
6. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13: 699-702.
7. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 1406-7.
8. Okamoto H, Yano K, Nozaki Y, et al. Mutations within the S gene of hepatitis B virus transmitted from mothers to babies immunized with hepatitis B immune globulin and vaccine. Pediatr Res 1992; 32: 264-8.
9. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169: 1374-6.
10. Ogata N, Miller RH, Ishaka KG, Zanetti AR, Purcell RH. Genetic and biological characterization of two hepatitis B variants: a precore mutant implicated in fulminant hepatitis and a surface mutant resistant to immunoprophylaxis. International Symposium on Viral Hepatitis and Liver Disease, 1994; 238-42.
11. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990; 8: S134-8.
12. Edmunds WJ, Medley GF, Nokes DJ. The transmission dynamics and control of hepatitis B virus in The Gambia. Stat Med 1996; 15: 2215-33.
13. McLean AR. Vaccination, evolution and changes in the efficacy of vaccines - a theoretical framework. Proc R Soc Lond B Biol Sci 1995; 261: 389-93.
14. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999; 17: 973-8.
15. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B Biol Sci 1993; 253: 197-201.
16. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford Science Publications, 1991.
17. McLean AR, Blumberg BS. Modelling the impact of mass vaccination against hepatitis B. I. Model formulation and parameter estimation. Proc R Soc Lond B Biol Sci 1994; 256: 7-15.
18. McLean AR, Nowak MA. Competition between zido vudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992; 6: 71-9.
19. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B Biol Sci 1993; 253: 9-13.
20. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995; 345: 1089-92.
21. Edmunds WJ, Medley GF, Nokes DJ. Vaccination against hepatitis B virus in highly endemic areas: waning vaccine-induced immunity and the need for booster doses. Trans R Soc Trop Med Hyg 1996; 90: 436-40.
22. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 1996; 117: 313-25.
23. Population and Housing Census (1983). The Republic of The Gambia, 1987.
24. Anderson RM, May RM. Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg 1985; 94: 365-436.
25. Edmunds WJ. The epidemiology and control of hepatitis B virus in highly endemic areas. Ph.D. thesis, Department of Biology, Imperial College, London, 1994.
26. Girones R, Miller RH. Mutation rate of the hepa-dnavirus genome. Virology 1989; 170: 595-7.
27. Nowak M, May RM. Superinfection and the evolution of parasite virulence. Proc R Soc Lond B Biol Sci 1994; 255: 81-9.
28. Andreasen V, Pugliese A. Pathogen coexistence induced by density-dependent host mortality. J Theor Biol 1995; 177: 159-65.
29. White LJ, Cox MJ, Medley GF. Cross immunity and vaccination against multiple microparasite strains. IMA J Math Appl Med Biol 1998; 15: 211-33.